Yue Zhao1, Yun Xie2, Dianjun Jia1, Chiluan Ma1, Dongdong Wei1, Xiaoyu Zhang3. 1. Department II of Radiotherapy, Cangzhou Central Hospital Cangzhou, China. 2. Hebei Provincial Center for Disease Control and Prevention Hebei, China. 3. Department III of Thyroid Breast Surgery, Cangzhou Central Hospital Cangzhou, China.
Abstract
OBJECTIVE: To analyze the value of gene polymorphisms in predicting the sensitivity of patients with locally advanced non-small-cell lung cancer (NSCLC) undergoing chemoradiotherapy. METHODS: Patients with locally advanced NSCLC undergoing chemoradiotherapy in our hospital from February 2017 to August 2019 were enrolled. X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms were detected before chemoradiotherapy, and the correlation of XRCC1 gene polymorphisms with the sensitivity was analyzed. RESULTS: There was no significant correlation of XRCC1 gene polymorphisms with age, gender, smoking status, pathological type, clinical stage and tumor size (P > 0.05). Among 98 patients with locally advanced NSCLC, 17 patients had complete response (CR), 25 patients had partial response (PR), 37 patients had stable disease (SD), and 19 patients had progressive disease (PD). A total of 42 patients were sensitive to chemoradiotherapy (CR + PR), and 56 patients were insensitive to treatment (SD + PD). The effect of XRCC1 gene polymorphisms on the efficacy of chemoradiotherapy was statistically significant (P < 0.05). In the codominant model GG vs. GA vs. AA, there was a significant difference (χ2 = 6.473, P = 0.039); The difference between AA and GA was significant (χ2 = 4.572, P = 0.032). The difference between AA and GG was significant (χ2 = 6.003, P = 0.014). There was no significant difference between GA and GG (χ2 = 0.015, P = 0.901). The rates of effective treatment for patients with XRCCI GG vs. GA vs. AA genotypes were 79.17%, 57.14%, and 47.37%, respectively. GG type was 1.38 times more effective than GA type, and GA type was 1.21 times more than AA type. CONCLUSION: The Arg399Gln polymorphism of XRCC1 gene was significantly related to the sensitivity of patients with locally advanced NSCLC undergoing chemoradiotherapy. The sensitivity of patients carrying wild-type gene AA to chemoradiotherapy was significantly better than that of patients with GA and GG. AJTR
OBJECTIVE: To analyze the value of gene polymorphisms in predicting the sensitivity of patients with locally advanced non-small-cell lung cancer (NSCLC) undergoing chemoradiotherapy. METHODS:Patients with locally advanced NSCLC undergoing chemoradiotherapy in our hospital from February 2017 to August 2019 were enrolled. X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms were detected before chemoradiotherapy, and the correlation of XRCC1 gene polymorphisms with the sensitivity was analyzed. RESULTS: There was no significant correlation of XRCC1 gene polymorphisms with age, gender, smoking status, pathological type, clinical stage and tumor size (P > 0.05). Among 98 patients with locally advanced NSCLC, 17 patients had complete response (CR), 25 patients had partial response (PR), 37 patients had stable disease (SD), and 19 patients had progressive disease (PD). A total of 42 patients were sensitive to chemoradiotherapy (CR + PR), and 56 patients were insensitive to treatment (SD + PD). The effect of XRCC1 gene polymorphisms on the efficacy of chemoradiotherapy was statistically significant (P < 0.05). In the codominant model GG vs. GA vs. AA, there was a significant difference (χ2 = 6.473, P = 0.039); The difference between AA and GA was significant (χ2 = 4.572, P = 0.032). The difference between AA and GG was significant (χ2 = 6.003, P = 0.014). There was no significant difference between GA and GG (χ2 = 0.015, P = 0.901). The rates of effective treatment for patients with XRCCI GG vs. GA vs. AA genotypes were 79.17%, 57.14%, and 47.37%, respectively. GG type was 1.38 times more effective than GA type, and GA type was 1.21 times more than AA type. CONCLUSION: The Arg399Gln polymorphism of XRCC1 gene was significantly related to the sensitivity of patients with locally advanced NSCLC undergoing chemoradiotherapy. The sensitivity of patients carrying wild-type gene AA to chemoradiotherapy was significantly better than that of patients with GA and GG. AJTR
Authors: Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis Journal: Clin Lung Cancer Date: 2009-03 Impact factor: 4.785
Authors: W Xu; Q Chen; Q Wang; Y Sun; S Wang; A Li; S Xu; O D Røe; M Wang; R Zhang; L Yang; J Zhou Journal: Cell Death Dis Date: 2014-12-04 Impact factor: 8.469